Sweden-based NeuroVive Pharmaceutical AB has appointed Magnus Hansson as its chief medical officer, effective 1 January 2016. He will lead clinical research and development, in particular, for clinical-stage products to treat traumatic brain injury and acute kidney injury. Dr Hansson has been worked on a part-time basis at the company as a scientific advisor. NeuroVive is developing medicines directed at mitochondrial dysfunction. Mitochondria are the organelles that generate energy for the cell.
Dr Hansson received his medical degree and PhD in experimental brain research from Lund University in Sweden and is the author of more than 30 scientific publications and 10 patent applications.
NeuroVive announced the appointment on 23 October 2015.
Copyright 2015 Evernow Publishing Ltd